Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH — Clinical Trial Site

23 Registered trials

10 Currently recruiting

Organisation

Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH

Location

Villingen-Schwenningen, Germany

Identifier

ORG-100046533

Address

Sonnhaldenstrasse 2, 78166, Germany

Departments

Clinic for internal medicine, Oncology, Hematology, Immunology, Infectiology & Palliativ Medicine
Hämatologie, Onkologie und Palliativmedizin
Hämatologie/Onkologie
Hematology
HNO Klinik
Innere Medizin II
Innere Medizin Onkologie
Klinik für Frauenheilkunde und Geburtshilfe
Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie (HNO)
Klinik für Innere Medizin II
Klinik für Innere Medizin II Onkologie/Hämatologie
Klinik für Innere Medizin II, Onkologie/Hämatologie
Klinik für Strahlentherapie und Radioonkologie mit MVZ
Klinik II für Innere Medizin
Lungenzentrum
N/A

Clinical trials at this site (23)

Search interface

Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending

2025-523990-40-00 Newly diagnosed Multiple Myeloma in patients eligible f 5
Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting

2025-520624-25-00 Secondary Hemophagocytic Lymphohistiocytosis (sHLH) 10 2025-09-19
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
PREFer Recruiting

2024-520138-31-00 Early-stage favorable classic Hodgkin lymphoma 4 2026-06-01
A Study to Learn About a Study Medicine Called Ibuzatrelvir in People With Coronavirus Disease 2019 (COVID-19) and a Severely Compromised Im… Recruiting

2024-517671-21-00 Coronavirus Disease 2019 (COVID-19) 5 2025-09-30
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with … Recruiting

2024-513862-20-00 Chronic Rhinosinusitis with Nasal Polyposis 5 2025-03-26
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Primary diffuse large B-cell lymphoma of the central ne 5 2023-08-09
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or … Recruiting

2023-507461-26-00 Newly diagnosed acute myeloid leukemia (AML) 5 2022-09-22
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Acute myeloid leukemia 5 2022-09-13
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516815-26-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-30
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Early-Stage Unfavorable Classical Hodgkin Lymphoma 4 2024-05-15
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined… Ended

2024-511577-29-01 intermediate and high-risk rectal cancer 5 2020-03-13
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens… Ended

2023-509305-68-00 Pulmonary arterial hypertension (PAH) 5 2019-05-16
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended

2023-509304-16-00 Pulmonary arterial hypertension (PAH) 5 2019-05-16
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15